{"product_id":"seed-vrio-analysis","title":"Origin Agritech Limited (SEED): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Origin Agritech Limited (SEED) truly positioned for sustainable success? This VRIO analysis cuts straight to the core, rigorously examining whether its current resources and capabilities are Valuable, Rare, Inimitable, and Organized to forge a lasting competitive advantage. Dive in now to uncover the definitive verdict on Origin Agritech Limited (SEED)'s strategic foundation and what it means for its future market dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrigin Agritech Limited (SEED) - VRIO Analysis: Proprietary GMO Trait Portfolio (BBL2-2 and others)\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core engine of Origin Agritech Limited's future value: their proprietary GMO traits, especially BBL2-2. This isn't just science; it's market access. The key takeaway is that the May 2024 safety certificate for BBL2-2 is the gate key to China's massive, regulated GMO seed market.\u003c\/p\u003e\n\n\u003ch\u003eValue: Market Access and Product Potential\u003c\/h\u003e\n\u003cp\u003eThe BBL2-2 trait portfolio is valuable because it unlocks entry into China's growing GMO seed market. The BBL2-2 maize received its Bio-Safety Certificate back in May 2024, which is the green light for high-value product sales, assuming final variety registration follows. This technology, which includes two insect-resistant genes (Cry1Ab and Cry3Bb) and one herbicide-tolerance gene (Cp4-epsps), promises farmers better pest management and potentially higher yields.\u003c\/p\u003e\n\n\u003ch\u003eRarity: First-Mover Regulatory Status\u003c\/h\u003e\n\u003cp\u003eHonestly, the rarity here is tied to regulatory history. While Origin Agritech's phytase corn was noted as the first transgenic corn to receive a Bio-Safety Certificate from China's Ministry of Agriculture years ago, the BBL2-2 certification establishes a current, critical lead in navigating the modern, stringent approval pathway for this specific triple-stack trait. It’s a unique regulatory achievement right now.\u003c\/p\u003e\n\n\u003ch\u003eImitability: High Barrier to Entry\u003c\/h\u003e\n\u003cp\u003eThis is hard to copy, and that's good for you. Gaining regulatory approval for novel traits like BBL2-2 requires years of expensive, government-monitored field trials. Competitors can't just buy this; they have to replicate the entire multi-year, multi-million dollar process. The R\u0026amp;D expenses for the first half of fiscal year 2025 were \u003cstrong\u003e$0.7 million\u003c\/strong\u003e, reflecting the ongoing investment required to build this pipeline.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Pipeline Execution\u003c\/h\u003e\n\u003cp\u003eOrigin is organized to push this pipeline. They aren't just sitting on the certificate; they are actively advancing multiple hybrids through the national trial system. Furthermore, they've formalized commercialization efforts, signing agreements with \u003cstrong\u003e12\u003c\/strong\u003e prominent agricultural companies in January 2025 alone to apply BBL2-2 technology. They are structured to monetize this asset.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage Assessment\u003c\/h\u003e\n\u003cp\u003eThe advantage is potentially sustained, but it hinges on execution. If they successfully commercialize the one hybrid currently on track for 2025 approval, this first-mover status in a major market will be locked in for a period. What this estimate hides is the risk of delays in the final variety registration process.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on their current pipeline progress:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Target\u003c\/th\u003e\n\u003cth\u003eSource\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBBL2-2 Safety Certificate Date\u003c\/td\u003e\n\u003ctd\u003eMay 2024\u003c\/td\u003e\n\u003ctd\u003eRegulatory Milestone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHybrids on Track for 2025 Approval\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNational Trial Progress (H1 FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHybrids on Track for 2026 Approval\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNational Trial Progress (H1 FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorn Varieties Being Improved with BBL2-2\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e100\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eConsortium Activity (as of H1 FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccumulated Corn Germplasm Resources\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e300,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Platform Strength\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eTo be fair, the operational structure is also being solidified to support this commercial push:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReceived GMO crop seed production license in October 2025.\u003c\/li\u003e\n\u003cli\u003eIncreased subsidiary registered capital from RMB 30 million (approx. \u003cstrong\u003e$4.2 million\u003c\/strong\u003e) to RMB 100 million (approx. \u003cstrong\u003e$14 million\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eEstablished the Origin Marker Biological Breeding Service Consortium in October 2024.\u003c\/li\u003e\n\u003cli\u003eAdvanced MIGC 20K chip technology using data from over \u003cstrong\u003e1,218\u003c\/strong\u003e inbred lines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday, focusing on capital needs for scaling hybrid production.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrigin Agritech Limited (SEED) - VRIO Analysis: Advanced Gene Editing Platform (Hi3 Technology \u0026amp; Cas-SF01 License)\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis of the Advanced Gene Editing Platform, encompassing the Hi3 Technology and the Cas-SF01 License, is structured around the VRIO framework.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a faster, more precise method for trait development, exemplified by the Hi3 technology recognized as a \u003cstrong\u003eTop 10\u003c\/strong\u003e Major Progress in Chinese Agricultural Science for \u003cstrong\u003e2025\u003c\/strong\u003e. The Hi3 technology can improve maize yield at high densities within a single year, saving \u003cstrong\u003e3-4 years\u003c\/strong\u003e compared to conventional backcrossing methods.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while gene editing is spreading, the specific, proven Hi3 system and the \u003cstrong\u003eNovember 2025\u003c\/strong\u003e patent license for Cas-SF01 are unique assets. The functional studies for the genes targeted (ZmRAVL1 and ZmDWF4) have been published in \u003cem\u003eScience\u003c\/em\u003e and \u003cem\u003eNature\u003c\/em\u003e, respectively.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate to High; the core technology is complex, but the Cas-SF01 license is a time-bound legal barrier. The agreement grants long-term access to IP-protected technologies. The expected final biosafety certification timeline is estimated to require \u003cstrong\u003e1-2 years\u003c\/strong\u003e due to regulatory procedures.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The R\u0026amp;D expenses of \u003cstrong\u003e$0.7 million\u003c\/strong\u003e in H1 \u003cstrong\u003e2025\u003c\/strong\u003e show they are investing to exploit this platform. The company reported total operating expenses of \u003cstrong\u003e$4.6 million\u003c\/strong\u003e for the six months ended March 31, 2025. The company had cash and cash equivalents of approximately \u003cstrong\u003e$0.33 million\u003c\/strong\u003e as of March 31, 2025.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes key data points related to the platform's investment and recognition:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003cth\u003eContext\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eH1 FY2025 (ended March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003eReflects continued development of new proprietary products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHi3 Technology Recognition\u003c\/td\u003e\n\u003ctd\u003eTop 10 Major Progress\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eAwarded by the Chinese Academy of Agricultural Sciences\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCas-SF01 License Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 10, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eAgreement with Shandong Shunfeng Biotechnology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime Savings (Hi3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3-4 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to conventional backcrossing\u003c\/td\u003e\n\u003ctd\u003eAccelerates yield improvement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosafety Certification Estimate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1-2 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-license\u003c\/td\u003e\n\u003ctd\u003eRegulatory timeline for edited lines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as gene editing tools are rapidly evolving, but the current IP access provides a near-term edge. The company aims to use this technology to develop corn varieties with optimized leaf angles that can be planted at higher densities. The company signed cooperation agreements with \u003cstrong\u003e12\u003c\/strong\u003e prominent agricultural companies in January \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company reported revenue of \u003cstrong\u003e$10.1 million\u003c\/strong\u003e for the first half of FY2025.\u003c\/li\u003e\n\u003cli\u003eNet loss attributable to the Company for H1 FY2025 was \u003cstrong\u003e$3.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLoss per ordinary share for H1 FY2025 was \u003cstrong\u003e$0.50\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrigin Agritech Limited (SEED) - VRIO Analysis: MIGC 20K Marker Technology\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eProprietary chip leveraging data from \u003cstrong\u003e40 million SNP sites\u003c\/strong\u003e across \u003cstrong\u003e1,218 inbred lines\u003c\/strong\u003e. \u003cstrong\u003e10 million detection data sites\u003c\/strong\u003e from over \u003cstrong\u003e2,000 breeding inbred lines\u003c\/strong\u003e in China are incorporated. Research and development expenses for Fiscal Year 2024 were \u003cstrong\u003eRMB 10.1 million (US$ 1.4 million)\u003c\/strong\u003e. Research and development expenses for the six months ended March 31, 2025, were \u003cstrong\u003e$0.7 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eData Component\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSNP Sites Leveraged\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInbred Lines (SNP Data)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,218\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Data Sites\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreeding Inbred Lines (Detection Data)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e2,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003ePlatform built on a proprietary dataset including \u003cstrong\u003e40 million SNP sites\u003c\/strong\u003e. The company has accumulated nearly \u003cstrong\u003e300,000 corn germplasm resources\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eRequires significant historical data collection, evidenced by the accumulated \u003cstrong\u003e300,000 corn germplasm resources\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eUnveiling occurred in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e. The 'Origin Marker Biological Breeding Service Consortium' was established in \u003cstrong\u003eOctober 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEstablished \u003cstrong\u003efour\u003c\/strong\u003e provincial and ministerial R\u0026amp;D platforms.\u003c\/li\u003e\n\u003cli\u003eConsortium working on improving over \u003cstrong\u003e100\u003c\/strong\u003e corn varieties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe data moat is supported by the consortium's scope, which established cooperative relationships with dozens of breeding companies across China.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrigin Agritech Limited (SEED) - VRIO Analysis: Strategic R\u0026amp;D Alliances (University\/Academy Partnerships)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eStrategic R\u0026amp;D Alliances (University\/Academy Partnerships)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eAccess to top-tier academic research, like the January 2025 partnership with China Agricultural University, accelerates innovation in 'smart plant type' improvement. The Company has established four provincial and ministerial R\u0026amp;D platforms and developed a large-scale corn genetic platform for efficient functional gene exploration.\u003c\/p\u003e\n\u003cp\u003eThe MIGC 20K technology, developed by the Marker Biological Breeding Platform, leverages data from 40 million SNP sites across 1,218 inbred lines.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024 (Full Year)\u003c\/th\u003e\n\u003cth\u003eH1 FY2025 (Six Months Ended March 31, 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (US$)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Prior Period H1)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.5 million\u003c\/strong\u003e (H1 FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerate; many firms partner, but securing a deal with a top-ranked institution is less common. China Agricultural University is cited as the 'world's top-ranked institution in agricultural science' in the context of the January 2025 collaboration.\u003c\/p\u003e\n\u003cp\u003eThe Company has accumulated nearly 300,000 corn germplasm resources.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerate; the relationship itself is hard to copy, but the knowledge transfer can be mimicked over time. The January 2025 alliance is a three-way partnership involving China Agricultural University and the Beijing Academy of Agricultural and Forestry Sciences.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe company actively highlights these collaborations as a core part of its future growth plan. In January 2025, the Company also signed cooperation agreements with 12 prominent agricultural companies.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Weibin Yan stated commitment to developing into an international seed enterprise with strong scientific research capabilities.\u003c\/li\u003e\n\u003cli\u003eThe Company's 2025 corporate development strategy includes strengthening its seed business and expanding its biotechnology platform capabilities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary, as these partnerships have defined terms, but they fuel near-term product flow. Research and development expenses increased from $0.5 million in H1 FY2024 to $0.7 million in H1 FY2025, reflecting continued development of new proprietary products.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrigin Agritech Limited (SEED) - VRIO Analysis: Biotech Service Consortium \u0026amp; Licensing Network\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the 'Origin Marker Biological Breeding Service Consortium,' established in October 2024.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe Consortium, established in \u003cstrong\u003eOctober 2024\u003c\/strong\u003e, generates potential royalty streams by improving over \u003cstrong\u003e100\u003c\/strong\u003e corn varieties for dozens of breeding companies. This structure is designed to accelerate the licensing and commercialization of Origin's GMO insect-resistant and herbicide-tolerant traits and gene editing technologies. The Company signed cooperation agreements with \u003cstrong\u003e12\u003c\/strong\u003e prominent agricultural companies in January 2025, focusing on BBL2-2 transgenic applications and molecular marker-based variety improvement.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsortium Establishment Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOrigin Marker Biological Breeding Service Consortium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorn Varieties Under Improvement\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e100\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of the six months ended March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreeding Company Relationships\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDozens\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEstablished across China\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecific Cooperation Agreements Signed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJanuary 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (Six Months Ended March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinancial result\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$0.33 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFinancial position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerate; service consortia are a known model, but Origin's specific network and access to proprietary trait pipelines, including the BBL2-2 maize with a GMO safety certificate from May 2024, make its offering unique in the current Chinese market structure.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerate; building trust and securing agreements with \u003cstrong\u003edozens\u003c\/strong\u003e of companies takes time and reputation, especially given the Company's established R\u0026amp;D platforms, including nearly \u003cstrong\u003e300,000\u003c\/strong\u003e corn germplasm resources.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThis structure directly supports their goal of becoming a high-tech seed service company led by biotechnology. The Company completed a strategic restructuring consolidating key production and sales entities under Beijing Origin, which is authorized for genetically modified (GMO) crop seed production, further aligning operations with the consortium's focus.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D Platforms Established:\u003c\/strong\u003e \u003cstrong\u003eFour\u003c\/strong\u003e provincial and ministerial R\u0026amp;D platforms.\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSubsidiary Capital Increase:\u003c\/strong\u003e Registered capital of Beijing Origin Seed Ltd. increased from RMB 30 million (US$\u003cstrong\u003e4.2 million\u003c\/strong\u003e) to RMB 100 million (US$\u003cstrong\u003e14 million\u003c\/strong\u003e).\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Portfolio:\u003c\/strong\u003e Holds \u003cstrong\u003enineteen\u003c\/strong\u003e Chinese patents related to seed products.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eSustained, as it creates a network effect where more partners make the consortium more valuable by increasing the volume of varieties being improved with Origin's technology, thereby expanding the potential for future royalty collection.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrigin Agritech Limited (SEED) - VRIO Analysis: Dual Regional Production\/Operation Licenses\n\u003c\/h2\u003e\n\u003cp\u003eThe dual licensing structure involves operational bases in Beijing and Xinjiang, China.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eHolding two crop seed production and operation licenses (Beijing and Xinjiang) allows for broader regional footprint and revenue diversification across complementary markets. The performance from Xinjiang operations was a key driver, with FY2024 revenue growing to \u003cstrong\u003eRMB 113.4 million (US$16.2 million)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; having two distinct, approved operational bases in key agricultural zones is a significant regulatory achievement.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHigh; regulatory approvals in China's seed sector are a major hurdle and time sink.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe October 2025 license from the Beijing Municipal Bureau of Agriculture and Rural Affairs directly expands their operational capacity, authorizing production, processing, packaging, wholesale, and retail of corn seeds. This follows a strategic restructuring where the registered capital of the subsidiary Beijing Origin Seed Ltd. was increased from \u003cstrong\u003eRMB 30 million (US$4.2 million)\u003c\/strong\u003e to \u003cstrong\u003eRMB 100 million (US$14 million)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe organizational structure supporting these licenses includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBeijing Origin Seed Ltd.\u003c\/strong\u003e: Increased registered capital to \u003cstrong\u003eRMB 100 million (US$14 million)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eXinjiang OriginBio Seed Limited\u003c\/strong\u003e: The other existing license holder, consolidated under Beijing Origin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eBeijing Entity Capital (Pre\/Post Increase)\u003c\/td\u003e\n\u003ctd\u003eRevenue Period\u003c\/td\u003e\n\u003ctd\u003eRevenue Amount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistered Capital\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRMB 30 million\u003c\/strong\u003e to \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended September 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRMB 113.4 million (US$16.2 million)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD Equivalent (New Capital)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUS$4.2 million\u003c\/strong\u003e to \u003cstrong\u003eUS$14 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSix Months Ended March 31, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRMB 72.34 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained, as regulatory barriers to entry are high. The inclusion of genetically modified (GMO) crop seed production in the Beijing business scope further solidifies this position, although individual GMO crop registrations are still required.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrigin Agritech Limited (SEED) - VRIO Analysis: Consolidated Operational Hub (Beijing Origin Seed Ltd.)\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the strategic consolidation under Beijing Origin Seed Ltd. as the primary operational hub.\u003c\/p\u003e\n\n\u003ch\u003eValue: The strategic restructuring consolidating entities under Beijing Origin Seed Ltd., which increased capital from \u003cstrong\u003e$4.2 million\u003c\/strong\u003e to \u003cstrong\u003e$14 million\u003c\/strong\u003e, creates operational efficiency and scalability.\u003c\/h\u003e\n\u003cp\u003eThe registered capital of Beijing Origin Seed Ltd. increased from \u003cstrong\u003eRMB 30 million\u003c\/strong\u003e (equivalent to \u003cstrong\u003e$4.2 million\u003c\/strong\u003e) to \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e (equivalent to \u003cstrong\u003e$14 million\u003c\/strong\u003e) in October 2025. This move consolidated key production and sales entities, including Xinjiang Originbo Seed Limited, under this hub.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePre-Restructuring\/Initial\u003c\/td\u003e\n\u003ctd\u003ePost-Restructuring\/Current\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeijing Origin Seed Ltd. Registered Capital (USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeijing Origin Seed Ltd. Registered Capital (RMB)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRMB 30 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eRMB 100 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated Entities\u003c\/td\u003e\n\u003ctd\u003eMultiple entities (e.g., Xinjiang Originbo Seed Limited)\u003c\/td\u003e\n\u003ctd\u003eKey production and sales entities consolidated under Beijing Origin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThis capital injection provides additional financial flexibility for investments in research and development, product innovation, and market expansion.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Low; corporate restructuring is common, but the specific consolidation under a newly capitalized entity is company-specific.\u003c\/h\u003e\n\u003cp\u003eThe consolidation establishes the company's primary operational hub, enhancing efficiency and supporting future scalability, particularly for serving the North China Plain agricultural region.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Low; competitors can restructure, but this specific integration is already done.\u003c\/h\u003e\n\u003cp\u003eThe integration of entities like Xinjiang Originbo Seed Limited under the newly capitalized Beijing Origin is a completed, company-specific action.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: This move establishes a primary operational hub, streamlining management and supporting future growth.\u003c\/h\u003e\n\u003cp\u003eThe organizational structure now features Beijing Origin as the central hub, streamlining operations and accelerating innovation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Company holds two crop seed production and operation licenses in China: one with Beijing Origin and another with its subsidiary Xinjiang OriginBio Seed Limited.\u003c\/li\u003e\n\u003cli\u003eThe Beijing Tongzhou District Market Supervision Administration approved the inclusion of genetically modified (GMO) crop seed production in the business scope.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary; it's an internal efficiency gain, not a market-facing barrier.\u003c\/h\u003e\n\u003cp\u003eThe operational efficiency gain is internal, though it supports the company's capacity to serve key markets. For the six months ended March 31, 2025, total operating expenses were \u003cstrong\u003e$4.6 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric (Six Months Ended March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (as of March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.33 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrigin Agritech Limited (SEED) - VRIO Analysis: Corn Germplasm Resource Accumulation\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the Corn Germplasm Resource Accumulation as a core asset.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAccumulation of nearly \u003cstrong\u003e300,000\u003c\/strong\u003e corn germplasm resources provides the raw material for all future breeding, both traditional and biotech. The Company has established four provincial and ministerial R\u0026amp;D platforms with research bases in Beijing, Hainan, and Henan.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eResource Metric\u003c\/th\u003e\n\u003cth\u003eQuantity\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorn Germplasm Resources Accumulated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNearly 300,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvincial\/Ministerial R\u0026amp;D Platforms\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIGC 20K SNP Sites Leveraged\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIGC 20K Inbred Lines Data Used\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,218\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIGC 20K Detection Data Sites Incorporated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; large seed companies have vast germplasm banks, but this specific, large collection is a key physical asset. The Company's biotechnology advancements include the MIGC 20K chip, which incorporates data from over 2,000 breeding inbred lines in China.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHigh; building a collection of this size takes decades of collection and preservation work. The R\u0026amp;D expenses reflect continued development, with $0.7 million in the first half of fiscal year 2025, compared to $0.5 million in the same period of fiscal year 2024.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThis resource underpins the R\u0026amp;D efforts mentioned in their partnerships. The Company signed cooperation agreements in January 2025 with 12 prominent agricultural companies. Financial position as of March 31, 2025, included $0.33 million in cash and cash equivalents and total borrowings of $0.69 million.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe germplasm supports the development of traits for which authorization has been received, including leaf angle, plant height, and rust resistance.\u003c\/li\u003e\n\u003cli\u003eThe resource supports the 'Origin Marker Biological Breeding Service Consortium' established in October 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained, as the physical collection is a long-term, non-replicable asset. The Company's phytase corn GMO received a Bio-Safety Certificate in 2009. One GMO hybrid is on track for potential approval in 2025, with two others targeted for 2026.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrigin Agritech Limited (SEED) - VRIO Analysis: CEO\/Insider Financial Commitment\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCEO\/Insider Financial Commitment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: CEO Weibin Yan's September 2025 investment of \u003cstrong\u003e\\$2.4 million\u003c\/strong\u003e signals strong internal confidence to investors, especially when cash is tight. As of March 31, 2025, the Company had approximately \u003cstrong\u003e\\$0.33 million\u003c\/strong\u003e in cash and cash equivalents.\u003c\/p\u003e\n\u003cp\u003eRarity: Low; insider buying happens, but the specific dollar amount of \u003cstrong\u003e\\$2,400,000\u003c\/strong\u003e and timing are unique to this event.\u003c\/p\u003e\n\u003cp\u003eImitability: Low; you can't imitate the CEO's personal decision to invest \u003cstrong\u003e2,000,000\u003c\/strong\u003e ordinary shares.\u003c\/p\u003e\n\u003cp\u003eOrganization: This action was used to bolster investor confidence during a period of operational investment, alongside an institutional investment of \u003cstrong\u003e\\$1,481,250\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary; it's a confidence booster, not a structural advantage. The company's financial health score is noted as \u003cstrong\u003e1.25\u003c\/strong\u003e out of \u003cstrong\u003e10\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance: Latest Available Cash Flow and Financial Metrics\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO Personal Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$2,400,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1,481,250\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Capital Infusion\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e\\$3.88 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSeptember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.33 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Borrowings\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.69 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-\\$20.0M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$113.38 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Earnings\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$20.71 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoss Per Ordinary Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix Months Ended March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.85M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional financial context includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses were \u003cstrong\u003e\\$0.7 million\u003c\/strong\u003e in the first half of fiscal year 2025.\u003c\/li\u003e\n\u003cli\u003eTotal operating loss for the first half year of FY2025 was \u003cstrong\u003e\\$3.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe stock price has decreased by \u003cstrong\u003e-50.00%\u003c\/strong\u003e in the last 52 weeks.\u003c\/li\u003e\n\u003cli\u003eThe company's market capitalization was reported at \u003cstrong\u003e\\$8.23 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEarnings for 2024 represented a decrease of \u003cstrong\u003e-62.57%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eThe number of shares outstanding has increased by \u003cstrong\u003e4.27%\u003c\/strong\u003e in one year.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516248055957,"sku":"seed-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/seed-vrio-analysis.png?v=1740202858","url":"https:\/\/dcf-model.com\/pt\/products\/seed-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}